^
    Back
    Association details:
    Biomarker:NF1 deletion
    Cancer:Glioblastoma
    Drug:Gomekli (mirdametinib) (MEK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    Cancer Res
    Title:

    Sensitivity of glioblastomas to clinically available MEK inhibitors is defined by neurofibromin 1 deficiency

    Excerpt:
    PD0325901 exposure suppressed the growth of LN229 tumors (Fig. 4B) and increased the survival of LN229-bearing animals...
    DOI:
    10.1158/0008-5472.CAN-12-0334